[go: up one dir, main page]

PL2968218T3 - Skojarzenie do leczenia choroby parkinsona - Google Patents

Skojarzenie do leczenia choroby parkinsona

Info

Publication number
PL2968218T3
PL2968218T3 PL14718177T PL14718177T PL2968218T3 PL 2968218 T3 PL2968218 T3 PL 2968218T3 PL 14718177 T PL14718177 T PL 14718177T PL 14718177 T PL14718177 T PL 14718177T PL 2968218 T3 PL2968218 T3 PL 2968218T3
Authority
PL
Poland
Prior art keywords
parkinson
disease
treatment
combination
Prior art date
Application number
PL14718177T
Other languages
English (en)
Inventor
Oron Yacoby-Zeevi
Original Assignee
Neuroderm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50513395&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2968218(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neuroderm Ltd filed Critical Neuroderm Ltd
Publication of PL2968218T3 publication Critical patent/PL2968218T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
PL14718177T 2013-03-13 2014-03-13 Skojarzenie do leczenia choroby parkinsona PL2968218T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361779357P 2013-03-13 2013-03-13
PCT/IL2014/050261 WO2014141261A1 (en) 2013-03-13 2014-03-13 Method for treatment of parkinson's disease
EP14718177.0A EP2968218B1 (en) 2013-03-13 2014-03-13 Combination for the treatment of parkinson's disease

Publications (1)

Publication Number Publication Date
PL2968218T3 true PL2968218T3 (pl) 2022-01-10

Family

ID=50513395

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14718177T PL2968218T3 (pl) 2013-03-13 2014-03-13 Skojarzenie do leczenia choroby parkinsona

Country Status (21)

Country Link
US (4) US20160022573A1 (pl)
EP (2) EP2968218B1 (pl)
JP (2) JP6472391B2 (pl)
KR (1) KR102209353B1 (pl)
CN (2) CN105209029A (pl)
AU (1) AU2014229127B2 (pl)
BR (1) BR112015022390A8 (pl)
CA (1) CA2904838C (pl)
CL (1) CL2015002641A1 (pl)
DK (1) DK2968218T3 (pl)
ES (1) ES2889626T3 (pl)
HR (1) HRP20211442T1 (pl)
HU (1) HUE056006T2 (pl)
IL (1) IL266648B (pl)
MX (1) MX365206B (pl)
PL (1) PL2968218T3 (pl)
PT (1) PT2968218T (pl)
RU (2) RU2018144700A (pl)
SG (2) SG11201507538UA (pl)
WO (1) WO2014141261A1 (pl)
ZA (1) ZA201507621B (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2678839C2 (ru) 2009-05-19 2019-02-04 Неуродерм Лтд Композиции для непрерывного введения ингибиторов допа-декарбоксилазы
RS57047B1 (sr) 2010-11-15 2018-05-31 Neuroderm Ltd Neprekidno davanje l dope, inhibitora dopa dekarboksilaze, inhibitora katehol-o-metil transferaze i kompozicije za iste
PL2640370T3 (pl) 2010-11-15 2018-09-28 Neuroderm Ltd Kompozycje do dostarczania przezskórnego substancji czynnych
HUE052642T2 (hu) * 2014-03-13 2021-05-28 Neuroderm Ltd DOPA dekarboxiláz inhibitor készítmények
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
PL3782617T3 (pl) 2014-09-04 2024-06-24 Lobsor Pharmaceuticals Aktiebolag Farmaceutyczne kompozycje żelowe zawierające lewodopę, karbidopę i entakapon
JP6567049B2 (ja) 2014-10-21 2019-08-28 アッヴィ・インコーポレイテッド カルビドパおよびｌ−ドーパプロドラッグならびにそれらの使用方法
MA41377A (fr) 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation
US10555922B2 (en) 2015-09-04 2020-02-11 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
WO2017070293A1 (en) * 2015-10-20 2017-04-27 Ironwood Pharmaceuticals, Inc. Phosphodiesterase 9 inhibitor and levodopa therapy
EP3275433A1 (en) * 2016-07-29 2018-01-31 Som Innovation Biotech S.L. Sustained release composition comprising micronized tolcapone
PT3634384T (pt) * 2017-06-05 2021-04-29 Dizlin Pharmaceuticals Ab Solução para infusão de levodopa
WO2019097120A1 (en) * 2017-11-16 2019-05-23 Orion Corporation New use and pharmaceutical dosage forms
US11806326B2 (en) 2018-01-29 2023-11-07 Jonathan Sackner-Bernstein Methods for dopamine modulation in human neurologic diseases
JP2021517128A (ja) * 2018-03-29 2021-07-15 アヴィオン ファーマシューティカルズ、リミティッド ライアビリティ カンパニー レボドパ分割用量組成物および使用
SG11202104499RA (en) 2018-11-15 2021-05-28 Abbvie Inc Pharmaceutical formulations for subcutaneous administration
CN111701024B (zh) * 2020-05-26 2022-05-24 上海京新生物医药有限公司 一种左旋多巴制剂及其制备方法及其应用
JP2023538859A (ja) * 2020-08-31 2023-09-12 パーデュー、ファーマ、リミテッド、パートナーシップ レボドパ送達のための組成物及び方法
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
WO2023282900A1 (en) * 2021-07-08 2023-01-12 Morehouse School Of Medicine Method and system of diagnosing and treating neurodegenerative disease and seizures
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
FI109453B (fi) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
EP2335696A1 (en) * 2005-06-08 2011-06-22 Orion Corporation An entacapone-containing oral dosage form
TR200806646A2 (tr) * 2008-09-03 2009-06-22 Dr. F. Fri̇k İlaç San. Ve Ti̇c. A.Ş. Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar
RU2678839C2 (ru) * 2009-05-19 2019-02-04 Неуродерм Лтд Композиции для непрерывного введения ингибиторов допа-декарбоксилазы
RS57047B1 (sr) 2010-11-15 2018-05-31 Neuroderm Ltd Neprekidno davanje l dope, inhibitora dopa dekarboksilaze, inhibitora katehol-o-metil transferaze i kompozicije za iste

Also Published As

Publication number Publication date
SG11201507538UA (en) 2015-10-29
JP2016512230A (ja) 2016-04-25
CA2904838C (en) 2021-03-16
MX365206B (es) 2019-05-27
RU2015143112A (ru) 2017-04-20
MX2015012561A (es) 2016-06-28
CA2904838A1 (en) 2014-09-18
KR20150131230A (ko) 2015-11-24
AU2014229127B2 (en) 2018-04-05
CL2015002641A1 (es) 2016-03-18
JP6472391B2 (ja) 2019-02-20
KR102209353B1 (ko) 2021-01-29
US20210093560A1 (en) 2021-04-01
JP6625773B2 (ja) 2019-12-25
IL266648A (en) 2019-07-31
US20250177292A1 (en) 2025-06-05
RU2677278C2 (ru) 2019-01-16
CN105209029A (zh) 2015-12-30
US20230047847A1 (en) 2023-02-16
ES2889626T3 (es) 2022-01-12
BR112015022390A2 (pt) 2017-07-18
SG10201911731YA (en) 2020-02-27
ZA201507621B (en) 2019-04-24
EP2968218B1 (en) 2021-07-07
PT2968218T (pt) 2021-09-24
US20160022573A1 (en) 2016-01-28
EP3892266A1 (en) 2021-10-13
HRP20211442T1 (hr) 2022-02-04
DK2968218T3 (da) 2021-09-20
AU2014229127A1 (en) 2015-11-05
RU2018144700A (ru) 2019-02-18
BR112015022390A8 (pt) 2019-11-26
CN110935026A (zh) 2020-03-31
JP2019070041A (ja) 2019-05-09
WO2014141261A1 (en) 2014-09-18
IL266648B (en) 2020-08-31
EP2968218A1 (en) 2016-01-20
HUE056006T2 (hu) 2022-01-28

Similar Documents

Publication Publication Date Title
IL280530A (en) Decarboxylase aromatic amino acid-encoding phylonucleotides for the treatment of Parkinson's disease
PL2968218T3 (pl) Skojarzenie do leczenia choroby parkinsona
SG11202012656WA (en) Heterocyclic compounds useful in the treatment of disease
PL3811943T3 (pl) Związek do stosowania w leczeniu zaburzeń oczu
IL243976A0 (en) kdm1a inhibitors for disease treatment
SG10201912275YA (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3kd related disorders
IL263188B (en) Treatment for Parkinson's disease
EP3086846A4 (en) Diagnosing and treating alzheimer's disease
HUE045148T2 (hu) Bumetanid parkinson-szindrómás neurodegeneratív betegségek kezelésére
IL243637A0 (en) PPAR-sparing compounds for the treatment of metabolic diseases
DK3148588T3 (en) N,n-bis-2-mercaptoethyl isophthalamide for the treatment of parkinson's disease
HK40097140A (en) Methods for the treatment of mitochondrial disease
PL3016948T3 (pl) 2-acyloaminotiazole do leczenia nowotworów
GB201320506D0 (en) Cyclic amino compounds for the use in the treatment of cardiac disorders
HK40032828A (en) Methods for the treatment of mitochondrial disease
ZA201807944B (en) Treatment for parkinson's disease
IL241482A0 (en) A method for treating Parkinson's disease
GB201518052D0 (en) Parkinson's disease treatment
GB201504144D0 (en) Treatment of Parkinson's disease
GB201310101D0 (en) Treatment of freidreich's ataxia
GB201306413D0 (en) The local treatment of ophthalmic diseases
EP2970118A4 (en) COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
GB201321628D0 (en) Treatment of disease
GB201304393D0 (en) Time's tremor